NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis $7.10 -0.47 (-6.21%) Closing price 04:00 PM EasternExtended Trading$7.18 +0.08 (+1.06%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Evolus Stock (NASDAQ:EOLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evolus alerts:Sign Up Key Stats Today's Range$7.02▼$7.6150-Day Range$7.14▼$9.3052-Week Range$3.86▼$9.31Volume761,677 shsAverage Volume1.00 million shsMarket Capitalization$468.96 millionP/E RatioN/ADividend YieldN/APrice Target$14.50Consensus RatingModerate Buy Company Overview Evolus, Inc. is a commercial-stage medical aesthetics company focused on developing and marketing products for healthcare providers and consumers. The company’s portfolio is designed to address facial wrinkles, folds and other signs of aging through injectable aesthetic treatments. Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines in adults. The company markets Jeuveau in the United States and sells the product internationally under the Nuceiva brand in certain markets. The company has expanded beyond neuromodulators with its Evolysse collection of injectable hyaluronic acid dermal fillers, which is intended to address facial volume loss and wrinkles. Evolus also provides digital tools and practice-support services intended to help aesthetic providers manage patient engagement, treatment education and product purchasing. Based in Newport Beach, California, Evolus was founded in 2012 and became a publicly traded company in 2018. David A. Moatazedi has served as the company’s president and chief executive officer since 2018. Evolus primarily serves aesthetic healthcare providers and patients in the United States, with additional international operations and distribution.AI Generated. May Contain Errors. Read More Evolus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreEOLS MarketRank™: 2.819793975745 of 5 starsEvolus scored higher than 56% of companies evaluated by MarketBeat, and ranked 521st out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingEvolus has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEvolus has a consensus price target of $14.50, representing about 102.7% upside from its current price of $7.16.Amount of Analyst CoverageEvolus has only been the subject of 2 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.36) to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -13.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -13.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evolus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.97% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 9.33.Change versus previous monthShort interest in Evolus has recently increased by 1.76%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment0.99 News SentimentEvolus has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Evolus this week, compared to 3 articles on an average week.Search Interest9 people have searched for EOLS on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows3 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $950,176.00 in company stock.Percentage Held by Insiders5.00% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EOLS Stock News HeadlinesEvolus, Inc. Enters into Option Agreement with Privately Held Company for Novel Injectable Hair Restoration ProgramOctober 14 at 12:38 PM | marketscreener.comMEvolus Expands Innovation Pipeline with Novel Injectable Hair Restoration ProgramOctober 14 at 12:38 PM | markets.ft.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 16 at 1:00 AM | Investors Alley (Ad)Evolus Signs Option Agreement With Company Developing Injectable Treatment for Hair RestorationOctober 14 at 12:38 PM | marketscreener.comMEvolus Expands Innovation Pipeline with Novel Injectable Hair Restoration ProgramOctober 14 at 9:00 AM | businesswire.comEOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS LawOctober 12, 2026 | businesswire.comARS Pharmaceuticals (NASDAQ:SPRY) vs. Evolus (NASDAQ:EOLS) Head-To-Head ComparisonOctober 9, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSOctober 8, 2026 | prnewswire.comSee More Headlines EOLS Stock Analysis - Frequently Asked Questions How have EOLS shares performed this year? Evolus' stock was trading at $6.65 at the beginning of the year. Since then, EOLS shares have increased by 7.6% and is now trading at $7.1550. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) released its quarterly earnings results on Monday, May, 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.02. The business had revenue of $73.14 million for the quarter, compared to analyst estimates of $72.52 million. Read the conference call transcript. When did Evolus IPO? Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' top institutional investors include Assenagon Asset Management S.A. (0.99%), Krilogy Financial LLC (0.02%) and GAMMA Investing LLC. Insiders that own company stock include Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Tomoko Yamagishi-Dressler, Brady Stewart, Albert G White III, David N Gill and David N Gill. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Canopy Growth (CGC), Micron Technology (MU), Tesla (TSLA), Palantir Technologies (PLTR) and Alibaba Group (BABA). Company Calendar Last Earnings5/04/2026Today10/16/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EOLS's financial health is in the Green zone, according to TradeSmith. EOLS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EOLS CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees353Year Founded2014Price Target and Rating Average Price Target for Evolus$14.50 High Price Target$17.00 Low Price Target$13.00 Potential Upside/Downside+104.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.64 million Net Margins-10.85% Pretax Margin-10.64% Return on EquityN/A Return on Assets-13.00% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.28 Sales & Book Value Annual Sales$297.18 million Price / Sales1.57 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-19.65Miscellaneous Outstanding Shares66,050,000Free Float62,748,000Market Cap$467.30 million OptionableOptionable Beta1.33 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:EOLS) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
